Updated on 13 September 2026
Medicinal product regulatory framework and authorisation in the EU
Senior Expert at Latvian Council of Science
Riga, Latvia
About
Experience with medicinal product regulatory framework and authorisation in the EU. Previously member of the Committee for Advanced Therapies at the European Medicines Agency (EMA), and external consultant for biologics and ATMPs at the National Medicines Agency (ZVA). Evaluation and consultation on cell and gene therapy authorisation submissions. Co-founder/CEO of biotech start-up company "InCell". Expert and National Programme Committee delegate for R&I programme "Horizon 2020" Health and Biotech topics since 2017. Now covering Cluster Health and Cancer Mission for "Horizon Europe" (2021-2027), the largest EU funding programme for research and innovation. Assistant Professor and Head of Bioanalytical Laboratory at University of Latvia, 2005–2018.
Topic
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-14-two-stage Clinical trials for advancing innovative interventions for neurodegenerative diseases
Type
- Partner seeks Consortium/Coordinator
Similar opportunities
Project cooperation
The Centre for Innovative Medicine (IMC)
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-01-two-stage Innovative healthcare interventions for non-communicable diseases
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-14-two-stage Clinical trials for advancing innovative interventions for neurodegenerative diseases
- Healthcare innovations: HORIZON-HLTH-2027-01-CARE-02 Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Digital health and AI: HORIZON-HLTH-2027-02-TOOL-01-two-stage Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
Tatjana Ivaskiene
General manager at State Research Institute Centre for Innovative Medicine
Vilnius, Lithuania
Project cooperation
The Centre for Innovative Medicine (IMC)
- Partner seeks Consortium/Coordinator
- Consortium/Coordinator seeks Partners
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-01-two-stage Innovative healthcare interventions for non-communicable diseases
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-14-two-stage Clinical trials for advancing innovative interventions for neurodegenerative diseases
- Healthcare innovations: HORIZON-HLTH-2027-01-CARE-02 Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Digital health and AI: HORIZON-HLTH-2027-02-TOOL-01-two-stage Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
Tatjana Ivaskiene
General manager at State Research Institute Centre for Innovative Medicine
Vilnius, Lithuania
Project cooperation
- Partner seeks Consortium/Coordinator
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-01-two-stage Innovative healthcare interventions for non-communicable diseases
Sławomir Jaros
CSO, CQO at ArThec
Łódź, Poland